Florida is currently home to 3760 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC
Recruiting
The purpose of this study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Hepatocellular Carcinoma
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 As Monotherapy and Combination Therapy in Subjects with BRAF V600 Mutant Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B) or Cetuximab (CFT1946 + cetuximab; Arm C).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Solid Tumors, Melanoma, NSCLC, CRC, ATC
LGMD R1 Natural History Study
Recruiting
This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
Gender:
ALL
Ages:
Between 12 years and 50 years
Trial Updated:
03/07/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Recruiting
Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of two groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk) myelodysplastic syndromes (LR MDS) and lower risk chronic my... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/07/2025
Locations: H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Myeloid Diseases
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Recruiting
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Orlando Health UF Health Cancer Center, Orlando, Florida
Conditions: Advanced Solid Tumors
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to \<6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of t... Read More
Gender:
ALL
Ages:
Between 6 months and 5 years
Trial Updated:
03/07/2025
Locations: Prohealth Research Center, Doral, Florida
Conditions: SARS-CoV-2
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
Recruiting
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part C is to evaluate the safety and reactogenicity of mRNA-1189 in 10- to 21-year-old healthy adolescents and adults.
Gender:
ALL
Ages:
Between 10 years and 30 years
Trial Updated:
03/07/2025
Locations: Research Centers of America - ERG, Hollywood, Florida
Conditions: Epstein-Barr Virus Infection
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Recruiting
This phase II trial studies the effect of pemetrexed and pembrolizumab in treating patients with salivary gland cancer that has come back (recurrent) and/or has spread to other places in the body (metastatic). Chemotherapy drugs, such as pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune sys... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Adenoid Cystic Carcinoma
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Recruiting
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: University of Florida, Jacksonville, Florida
Conditions: Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Recruiting
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2025
Locations: Boca Raton Medical Institute, Boca Raton, Florida
Conditions: Obsessive-Compulsive Disorder
Cancer Genetic Testing in Ethnic Populations
Recruiting
This clinical trial examines the integration of cancer genetic testing in various ethnic populations. Studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk. The information from this study may provide an opportunity for cancer risk stratification and individualized screening in these ethnic populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Breast Carcinoma, Carcinoma of Unknown Primary, Central Nervous System Carcinoma, Digestive System Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma, Malignant Brain Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Musculoskeletal Neoplasm, Malignant Solid Neoplasm, Skin Carcinoma
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
Recruiting
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Miami Cancer Institute, Miami, Florida
Conditions: Glioblastoma Multiforme